Regeneron Pharmaceuticals, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $8.00 | — | — | Miss |
| Q12026 FY2026 | $6.28 | $7.50 | +19.4% | Beat |
| Q42025 FY2025 | $8.28 | $9.90 | +19.6% | Beat |
Back to REGN overview · REGN holders · REGN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.